Abstract
Traditional vaccine methods have long been employed to control widespread infectious diseases, but so far, all commercially available vaccine strategies have been inadequate in efforts to develop an effective therapeutic HIV vaccine. However, recent advancements in immunological research have lead to the generation of novel vaccine strategies, one of which is the recombinant virus vaccine, a method of particular interest that has shown promise in the clearance of HIV infection within HIV-positive patients who have retained immunocompetence.
This study examined the stability of the expression of HIV-1 genes, gag and env, through a recombinant virus vector, a recombinant vesicular stomatitis virus (VSV), a temperaturesensitive mutant genetically modified to contain the select HIV-1 genes (VSVInd(GML)HIV1gag-env). For SDS-PAGE, incubation was at 31 °C and 37 °C, the permissible and semipermissible growth conditions respectively for VSVInd(GML) temperature-sensitive mutants.
Western blot analysis was used to quantitate levels of protein expression of full VSV proteins, Gag and Env, using a primary rabbit antibody of anti-VSV anti-serum and a secondary anti-IgG from rabbit, a primary antibody of anti-p24 anti-serum and a secondary anti-IgG from rabbit, and a primary goat antibody of anti-gp120, and a secondary anti-IgG from goat. Results indicated that the VSVInd(GML) vector system allowed for high levels of expression of HIV-1 gag and env genes. It is known that the expression of these genes induces the production of major neutralizing antibodies and the stimulation of cytotoxic T lymphocytes, revealing the potential to use a genetically modified recombinant VSV as a universal vector for the development of recombinant virus vaccines. Specifically, the VSVInd(GML) mutant vector is thus an attractive candidate for the viral vector of a therapeutic HIV vaccine system.
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Background and Rationale
According to the World Health Organization report in 2013, HIV has infected over 70 million people and 36 million have died from AIDS-related illnesses since 1981. Additional reports from United Nations AIDS disclosed that 2.3 million were newly infected in 2012, adding to a total of 35.3 million people diagnosed with HIV infection as of 2013. HIV/AIDS is a rising world epidemic and our search for a method to control the spread of this disease has presented one of the most challenging problems of the past three decades.
Vaccines are one of the most effective methods of controlling infectious disease and thus a central focus for HIV treatment has been on efforts to develop an effective therapeutic vaccine that will clear HIV infection. There are three types of commercially available vaccine strategies that are used to prevent many different viral diseases. These include the live-attenuated virus vaccine, such as the measles and mumps vaccines, the killed whole-virus vaccine, which has been used to prevent influenza virus and hepatitis A virus infection, and subunit vaccines, such as human hepatitis B virus and human papilloma virus vaccines. However, these three conventional vaccine strategies have so far proved inadequate for use as therapeutic HIV vaccine systems, effectively demonstrating our limited and largely empirically-based knowledge of these technologies and our lack of a comprehensive understanding of the immunological principles underlying widespread infectious diseases such as HIV (Luo, Li, & Kang, 2003; Hanke, 2001; Nature, 2009) . Recent advancements however, have resulted in the generation of novel vaccine strategies, one of which is the recombinant virus vaccine, a method that has shown to be promising in clearance of HIV infection within HIV-positive patients who have retained immunocompetence.
Recombinant virus vaccines depend on the use of a viral vector to carry genes of interest, such as HIV genes, and express them in the body to activate CD8 positive cytotoxic T lymphocytes (CTLs). Development of a therapeutic HIV vaccine to clear persistently infected cells centers around the stimulation of adaptive host immune responses, in particular, the induction of antibody-dependent cellular cytotoxicity and the activation of viral-specific CTLs to destroy and clear HIV-infected cells (Kang, Luo, Wainberg, & Li, 1999) . In particular, CTL response is considered a major immune defense mechanism required for recovery from nearly all viral infections (Luo et al., 1998) . It is not desirable to use live HIV for CTL activation, but through a recombinant virus vaccine, it is possible to express selected HIV genes, which will activate HIV-specific CTLs.
The stimulation of HIV-specific CTLs also depends on the HIV genes chosen for expression through the recombinant viral vector. HIV is a retrovirus with a genome expressing three major structural proteins, Gag (capsid protein, matrix protein), Pol (reverse transcriptase, RNase H, Integrase, protease) and Env (gp120 and gp41) (Goff, 2006) . Particularly relevant are HIV-1 gag and env genes of which can play critical roles in the induction of adaptive-host immune responses (Kang, Luo, Wainberg, & Li, 1999) . Gag, group-specific antigen, facilitates viral assembly and maturation (Ono, Orenstein, & Freed, 2000) . When gag is expressed without pol in recombinant virus-infected cells, the precursor Gag55 assembles virus-like particles (VLPs) that are non-infectious and mimic HIV virions (Luo, Li, Dales, &, Kang, 1994) . Env, envelope, comprises the Gp120 and Gp41 glycoproteins present on the surface of HIV as a trimer (Wu et al., 2009 ). Env precursor protein, Gp160, is synthesized in the endoplasmic reticulum and then transported to the Golgi where it is cleaved into Gp120 and Gp41 by cellular proteases. The surface protein, Gp120, attaches to the cellular receptors, CD4 and chemokine receptors, of susceptible cells to initiate infection. In a study performed by Luo et al. (1998) , it was found that HIV-1 Gag particles carrying multiple T-cell epitopes of Gp120 induced strong CTL responses.
In a related study, Kang et al., (1999) demonstrated that HIV-1 gag-env VLPs resulted in high CTL activity. HIV-1 gag and env genes have thus been identified as strong candidates for use in an HIV/AIDS vaccine system and are therefore the genes of interest for this experiment.
In this study, the viral vector selected for HIV-1 gene expression was an attenuated recombinant vesicular stomatitis virus (VSV), a member of the Rhabdoviridae family. VSV infects cattle, horses, and swine and, in humans, infection results in asymptomatic or mild flulike symptoms such as fever and malaise (Wu, Kim, & Kang, 2009 ). VSV has a negative-sense RNA genome containing 11,161 nucleotides, which encode five major viral structural proteins, the nucleocapsid protein (N), the phosphoprotein (P), the matrix protein (M), the glycoprotein (G), and the large protein (L) (Wagner, 1987; Lyles & Rupprecht, 2006; An, Kim, Wu, & Kang, 2013) .
VSV presents an attractive viral vector system due to its wide host range, rapid replication processes, and mild pathogenicity in humans . Kim and Kang (2007) found that mutations introduced into the M gene of VSV result in an attenuated virus that exhibits reduced inhibitory effects on host cell gene expression and results in significantly less cytopathic effects within infected cell lines, a finding allowing for the production of avirulent and temperature-sensitive VSV mutants. Most valuable is the existence of VSV in two serotypes; Indiana (VSVInd) and New Jersey (VSVNJ). Wu et al. (2009) found that both serotypes have the capacity to stably express foreign genes and exhibit no cross-neutralization, revealing the potential for use of both VSV serotypes in a prime and boost method of vaccine delivery.
In order for the recombinant VSV vector to be used for an effective therapeutic HIV vaccine, the VSV vector system must be capable of stably expressing the HIV genes carried, an issue appraised in this study. In this research, I evaluated the expression of HIV-1 gag and env genes by employing VSVInd(GML), an avirulent and temperature-sensitive mutant vector system.
High levels of HIV-1 gag and env gene expression by VSVInd(GML) indicate the potential for use of this viral vector system to activate CTLs and therefore confer immunity against infection through a therapeutic HIV vaccine. In this study, I describe the construction of the recombinant VSVInd(GML) vector, the recovery of the recombinant VSVInd(GML) mutant containing HIV-1 gag and env genes by reverse genetics, and the quantitation of levels of protein expression in cells infected with the recombinant VSVInd(GML) containing gag and env genes.
Hypothesis
It was hypothesized that the recombinant VSVInd(GML) vector would successfully express HIV-1 gag and env genes based on the reputation of the recombinant VSV as a tolerant viral vector that has already been identified as having the acute ability to effectively express a range of foreign genes, such as those of Marburg and Ebola viruses (Mire et al., 2012) .
Quantitating the expression levels of HIV-1 Gag and Env proteins through the VSVInd(GML) vector system will indicate the potential for application of a recombinant VSV mutant as a major player in prospective therapeutic HIV vaccine development.
Experimental Methods (1) Plasmid Construction
The recombinant VSVInd(GML)HIV-1gag-env vector was provided for this experiment; independent construction of the vector was not performed. However, the method of recombinant vector construction needs to be briefly addressed for clear understanding of the results. VSVInd(GML), an avirulent and temperature-sensitive mutant, was produced in the Kang Laboratory through the introduction of mutations at G21E, M51R, and L111A. Fusion of HIV-1 gag and env genes created a gag-env hybrid gene. The gag gene insert also contained 171 nucleotides that coded for T cell epitopes. The HIV-1 gag-env hybrid gene was inserted into the VSVInd(GML) genome between G and L genes of VSV by restriction enzyme Mlu1.
(2) Cell culturing
Baby Hamster Kidney21 (BHK21) cells were used to amplify recombinant VSVInd(GML)HIV-1gag-env. The cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 5.0% fetal bovine serum (Gibco BRL), antibiotics penicillin (100 μg/mL), streptomycin (100 μg/mL), and kanamycin (100 μg/mL), and L-Glutamine (2 mM). The cells were incubated in a 5.0% CO2 incubator at 37 °C for 17 hours and passaged when 100% confluent. 
(3) Transformation of E. coli DH5α
Competent Cell Preparation E. coli DH5α colonies were streaked on a SOB agar media without antibiotics and incubated overnight at 37 °C. Five isolated colonies were transferred into 100 mL of SOB liquid media without antibiotics and grown using a shaking incubator set to 210 rpm at 37 °C. Cells were recovered by centrifugation at 4500 rpm at 4 °C for 10 minutes. according to the manufacturer's specifications in order to recover the recombinant VSVInd(GML)HIV-1gag-env by the VSV recovery protocol (Kim & Kang, 2007) . Confluent BHKT7 cells were transfected with 19.4 μg of the plasmid containing VSVInd(GML)HIV-1gag-env and co-transfected with 10 μg of pKS-HP, 10 μg of pKS-HN, and 5 μg of pKS-HL plasmid DNA. VSV-specific RNA polymerase was expressed through transcription of N, P and L plasmid DNA by T7 RNA polymerase and N, P, and L mRNAs were translated by Internal Ribosome Entry Sites (IRES). VSVInd(GML)HIV-1gag-env was transcribed and replicated by VSV-specific RNA polymerase (N, P, L), trimmed by HDV ribozyme, and assembled as the recombinant virus.
Incubation was at 31 °C in a 5% CO2 incubator because the recombinant VSVInd(GML)HIV1gag-env is a temperature-sensitive mutant. The culture media was harvested when 80% of cells showed cytopathic effects (CPE), observed 96 hours post-transfection.
(6) Purification and determination of viral titer by plaque assay
Recovered virus, VSVInd(GML)HIV-1gag-env, was purified by three times plaque picking on BHK21 cells. The viral titer was then determined by a plaque assay in order to administer an infection at multiplicity of infection (MOI) of 0.1 to propagate the recovered VSVInd(GML)HIV-1gag-env and attain a viral stock. Recovered VSVInd(GML)HIV-1gag-env was first diluted 10 -4 , 10 -5 and 10 -6 times. A 6-well plate of confluent Vero cells was inoculated with 100 μL of each dilution and incubated at 37 °C for 17 hours. The resulting plaque numbers were counted and determined the virus titer. Confluent BHK21 cells were infected at an MOI of 0.1 with serum-free DMEM for propagation to attain a viral stock. A second plaque assay titration was performed repeating the same procedure in order to determine the viral titer of the viral stock for infection at an MOI of 6 to prepare the cell lysate for SDS-PAGE and Western blot analysis.
(7) SDS-PAGE and Western blot analysis
Infections at an MOI of 6 of confluent BHK21 cells were performed with VSVInd(GML)HIV-1gag-env and VSVInd(GML) without an insert as a negative control.
Incubation was at 31 °C and 37 °C, the permissible and semi-permissible growth conditions for VSVInd(GML) temperature-sensitive mutants. The protein in the cell lysate obtained from these infections was quantitated by UV spectrophotometry. The infected cell lysates were used to perform an SDS-PAGE followed by Western blot analysis. Blotting was performed using TBS-T buffer (0.1% Tween). Detection during Western blotting was performed to quantitate the expression of VSV proteins, Gag, and Env consecutively. For detection of VSV protein expression, a primary rabbit antibody of anti-VSV anti-serum was used with a secondary antiIgG from rabbit. Detection of Gag expression was performed with a primary rabbit antibody, anti-p24 anti-serum, and a secondary anti-IgG from rabbit. Detection of Env was then performed with primary goat antibody, anti-gp120, and a secondary anti-IgG from goat.
Results
(1) Gel electrophoresis of extracted DNA by maxi-preparation DNA gel electrophoresis was used to verify successful extraction of each plasmid. DNA gel electrophoresis was performed with DNA plasmids N, P, and L ( Fig. 1) and the recombinant vector, VSVInd(GML)HIV-1gag-env (Fig. 2) . Samples of extracted DNA plasmids were electrophoresed alongside corresponding stock control plasmids. Electrophoresis results showed that the fragment sizes of extracted plasmids with marker plasmids were identical, indicating the successful extraction of these plasmids from bacterial cultures.
(2) Recovery of VSVInd(GML)HIV-1gag-env by reverse genetics
Bacteriophage T7 RNA polymerase is constitutively expressed in BHKT7 cells and this RNA polymerase transcribes the transfected pVSVInd(GML)HIV-1gag-env cDNA genome and co-transfected N, P and L plasmids. An Internal Ribosome Entry Site (IRES) allowed translation of VSV N, P, and L proteins, the VSV-specific RNA polymerase. After initial transcription of the recombinant VSVInd(GML)HIV-1gag-env genome by T7 RNA polymerase, it was replicated and transcribed by VSV-specific RNA polymerase (N, P, and L proteins) and the recombinant Table 1 . Figure 4 . Recovery of VSVInd(GML)HIV-1gag-env using Reverse Genetics. BHKT7 cells are transfected with pVSVInd(GML)HIV-1gag-env and co-transfected with pN, pP, and pL. Culture media was harvested from transfected cells after observation of 80% CPE (Buchholz, Fink & Conzelmann, 1999 Similar results were shown in a study performed by Rose et al. (2000) , who demonstrated the use of a recombinant VSV to effectively express HIV-1 genes through the sequential boosting of mice with recombinant VSV vectors encoding the HIV-1 Env protein.
Table 1
Determination of Viral Titer of VSVInd(GML)-HIV-1gag-env
Results revealed a great increase in the production of HIV-specific neutralizing antibodies. CTL activation was not evaluated, but, a parallel study performed by Egan et al. (2004) , demonstrated a significant increase in CTL response in macaques with vaccination using recombinant VSVbased vectors expressing HIV-1 Env and simian-human immunodeficiency virus (SIV) Gag proteins. The observations presented by these studies determined the same conclusions discussed, identifying the ability of a recombinant VSV vector to express and process HIV-1 Gag and Env proteins. Such results have also been expanded upon in a study performed by Wu, Kim, & Kang (2009) who, in addition to highlighting the capability of the VSVInd(GML) vector system to express HIV-1 genes, found that its counterpart, the VSV New Jersey serotype, also possesses the ability to express HIV-1 gene, env (gp160), a finding that can be used in conjunction with this study's results to conclude the capability of both serotypes of VSV to express inserted HIV-1 genes. This suggests the potential of employing both VSV vector systems in the development of priming and boosting vaccines, using the VSV expression system to activate CD8 positive CTLs.
To conclude, VSVInd(GML)HIV-1gag-env is capable of expressing HIV-1 Gag and Env proteins at both permissive and semi-permissive temperatures. For application to a recombinant virus vaccine system, it is desirable to develop a RNA virus vector capable of accommodating large foreign genes, allowing high levels of foreign gene expression. Therefore, these positive results reveal the potential use of VSVInd(GML) as an efficient viral vector system for a candidate therapeutic HIV vaccine to clear chronic HIV infection. This presents optimistic prospects for the development of a vaccine system that can substitute the high prices of antiretrovirus therapeutic drugs with a cost-effective immunotherapy that will help clear infection from millions of people diagnosed with HIV.
Future Work
Future research currently focuses on the application of recombinant virus vaccine systems for the treatment of other infectious diseases such as the hepatitis C virus and even bacterial diseases such as tuberculosis. The results from this experiment suggest that additional projected studies of protective immune responses in animal models and the evaluation of the side-effects of recombinant virus vaccine systems may be beneficial to expand our knowledge of the immunological mechanisms underlying viral infections so that it may be possible to develop more effective and economic anti-viral therapies.
